you are here: Home News Pharma

Pharma

Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
Laurus Labs: Is the healthy growth already priced in?
Cough syrup deaths: Old regulatory failures resurface as CDSCO calls for ‘strict quality control’
Govt invites proposals under PRIP scheme for industry, startup projects
Select pharma shares fall between 4-7% as Trump's tariffs on branded drugs sour sentiment
InvAscent-backed Malladi Drugs planning Rs 1,200-crore IPO, holds talks with banks
Moneycontrol Pro Panorama | A Rs 1000-crore Rx heavyweight in the making
Relief for pharma sector as govt waives mandatory re-labelling of medicines after GST rate cut
GST rate cuts to benefit players across the healthcare sector
Trump doubles tariff from Aug 27: Indian labour-intensive goods face over 50%, pharma, tech remain spared
India's pharma, chemical tariffs lower compared to China
Sun Pharma: Innovative drugs are near-term growth drivers
How Novo Nordisk lost its lead in the weight loss race
Laurus Labs: Is it time to book profit?
Cipla: Non-US markets to drive growth in the near term
Cipla Q1FY26 preview: Margin pressure likely despite double-digit India growth
Dr Reddy’s Q1FY26 preview: US headwinds may weigh on margins but revenue may see double-digit growth
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
Cohance Lifesciences Q1 PAT may dip 64.2% YoY to Rs 51.6 cr: ICICI Securities
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end
A $2 billion shot in the arm: Why Glenmark’s AbbVie deal could trigger rerating
Impending jump in patent expiries to benefit Indian pharma
Indian pharma companies sit on record cash pile, set sights on acquisitions

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Pharma

Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates

Laurus Labs: Is the healthy growth already priced in?

Cough syrup deaths: Old regulatory failures resurface as CDSCO calls for ‘strict quality control’

Govt invites proposals under PRIP scheme for industry, startup projects

Select pharma shares fall between 4-7% as Trump's tariffs on branded drugs sour sentiment

InvAscent-backed Malladi Drugs planning Rs 1,200-crore IPO, holds talks with banks

Moneycontrol Pro Panorama | A Rs 1000-crore Rx heavyweight in the making

Relief for pharma sector as govt waives mandatory re-labelling of medicines after GST rate cut

GST rate cuts to benefit players across the healthcare sector

Trump doubles tariff from Aug 27: Indian labour-intensive goods face over 50%, pharma, tech remain spared

India's pharma, chemical tariffs lower compared to China

Sun Pharma: Innovative drugs are near-term growth drivers

How Novo Nordisk lost its lead in the weight loss race

Laurus Labs: Is it time to book profit?

Cipla: Non-US markets to drive growth in the near term

Cipla Q1FY26 preview: Margin pressure likely despite double-digit India growth

Dr Reddy’s Q1FY26 preview: US headwinds may weigh on margins but revenue may see double-digit growth

Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities

Cohance Lifesciences Q1 PAT may dip 64.2% YoY to Rs 51.6 cr: ICICI Securities

Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities

Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

A $2 billion shot in the arm: Why Glenmark’s AbbVie deal could trigger rerating

Impending jump in patent expiries to benefit Indian pharma

Indian pharma companies sit on record cash pile, set sights on acquisitions